A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Ohio State University Comprehensive Cancer Center
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Revolution Medicines, Inc.
Centre hospitalier de l'Université de Montréal (CHUM)
GlaxoSmithKline
Accent Therapeutics
A2 Biotherapeutics Inc.
National Institutes of Health Clinical Center (CC)
Revolution Medicines, Inc.
University of Colorado, Denver
GlaxoSmithKline
University of Nebraska
Natera, Inc.
Novartis
Institut du Cancer de Montpellier - Val d'Aurelle
Massive Bio, Inc.
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Sahlgrenska University Hospital
Elicio Therapeutics
Institut Bergonié
Guardant Health, Inc.
University of California, San Francisco
ModeX Therapeutics, An OPKO Health Company
Tempus AI
Esperas Pharma Inc.
Stanford University
Ohio State University Comprehensive Cancer Center
Mayo Clinic
Universitat Jaume I
Stanford University
Taproot Health
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
DxTerity Diagnostics
UTC Therapeutics Inc.
Jules Bordet Institute
University of Aarhus
Assiut University
Dublin City University
Institut de cancérologie Strasbourg Europe
Charite University, Berlin, Germany
Corvus Pharmaceuticals, Inc.
Charite University, Berlin, Germany
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
Klus Pharma Inc.
St Vincent's University Hospital, Ireland